Core Viewpoint - The company, Beijing Baipusi Biotechnology Co., Ltd., has shown significant growth in revenue and net profit, indicating a strong performance in the biotechnology sector, particularly in the recombinant protein market [2][3]. Group 1: Financial Performance - For the period from January to September 2025, the company achieved an operating income of 613 million yuan, representing a year-on-year growth of 32.26% [2]. - The net profit attributable to shareholders for the same period was 132 million yuan, reflecting a year-on-year increase of 58.61% [2]. - Cumulatively, the company has distributed a total of 432 million yuan in dividends since its A-share listing, with 312 million yuan distributed over the past three years [3]. Group 2: Shareholder and Market Activity - As of September 30, 2025, the number of shareholders decreased by 9.75% to 10,600, while the average number of circulating shares per person increased by 54.93% to 11,947 shares [2]. - The financing balance of the company was reported at 82.71 million yuan, which is 0.95% of the circulating market value, indicating a low level compared to the past year [1]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited holding 13.56 million shares, an increase of 7.57 million shares from the previous period [3].
百普赛斯12月23日获融资买入459.63万元，融资余额8270.84万元